Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Lung Neoplasms

Neoplasm Metastasis

Neoplastic Cells, Circulating

Neoplastic Processes

Vasoconstrictor Agents

Respiratory System Agents

All Drugs and Chemicals

Xylometazoline

Patients with histologically proven malignant pulmonary ground glass opacities (GGOs)

Patients with histologically or radiologically proven benign pulmonary ground glass opacities (GGOs)

Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA

cf DNA and ct DNA

Marco Anile, MD

Massimiliano Bassi, MD

The aim of the study is the early and non-invasive diagnosis of lung cancer in patients with pulmonary ground glass opacity. In particular, objective of the study is to evaluate the presence or absence of circulating tumor DNA (ctDNA) on the peripheral blood of patients with evidence of ground glass opacity(GGO) at CT scan and to evaluate the role that this can play in the diagnostic / therapeutic process. The ctDNA evaluation will be performed at the first radiological finding and subsequently correlated with the malignancy of the lesion based on the radiological / histological criteria regularly used in international protocols.

Secondary objective is the correlation, in patients with malignant GGO undergoing surgical treatment, of the ctDNA presence and tumor spread through the air spaces (STAS), and its correlation with local relapses.

patients serum from peripheral blood samples

Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs

Impact of Circulating Tumor DNA on Early Cancer Detection and Evaluation of STAS in Patients With Ground Glass Opacities

Assess quantity of the circulating free DNA measured in ng/μL using Qubit 2.0

Number of participants with of circulating tumor DNA using a lung pannel for genes: EGFR, KRAS, NRAS, TP53, SKT11, DDR2, PIK3CA, FGFR3, CTNNB1, MET, BRAF, ERBB2, SMAD4, PTEN, AKT, FGFR2, ERBB4, NOTCH1, FGFR1, ALK, IDH1, HRAS, IDH2, PDGFRA, RET, ROS1

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs	NCT05187767	Lung Cancer Spreading of Tu... Circulating Tum...	cf DNA and ct D...	18 Years -	University of Roma La Sapienza
Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs	NCT05187767	Lung Cancer Spreading of Tu... Circulating Tum...	cf DNA and ct D...	18 Years -	University of Roma La Sapienza
Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs	NCT05187767	Lung Cancer Spreading of Tu... Circulating Tum...	cf DNA and ct D...	18 Years -	University of Roma La Sapienza

Spots Global Cancer Trial Database for cf dna and ct dna